ArticleScience advances2020
Nanovesicles derived from iron oxide nanoparticles-incorporated mesenchymal stem cells for cardiac repair.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.
- Advances in the study of exosomes in cardiovascular diseases.Journal of advanced research · 2024Pooled it
- Spatiotemporal Nanotherapy After Myocardial Infarction: Targeting the Inflammatory-to-reparative Transition With Extracellular Vesicles and Engineered Nanoparticles.Cardiovascular drugs and therapy · 2026Review
- How is Nanoarchitectonics Shaping Extracellular Vesicle Research?Advanced healthcare materials · 2026Review
- Biomaterial-Assisted Stem Cell Therapy and Exosome Delivery in Myocardial Infarction: A Narrative Review.Biomimetics (Basel, Switzerland) · 2026Review
- Extracellular Vesicles as Nanoparticle Delivery Vectors in Cancer Therapy.Nano letters · 2026Review
- Dual-targeted engineered mesenchymal stem cell-derived extracellular vesicles delivering Nedd4 attenuate renal fibrosis in diabetic kidney disease.Materials today. Bio · 2026Article
- Extracellular Vesicles in Myocardial Infarction: Dual Role in Ferroptosis Regulation and In Vivo Imaging.Diagnostics (Basel, Switzerland) · 2026Review
- Stem Cells and Their Derivatives in Cardiac Fibrosis Therapy: Challenges and Perspectives.Cells · 2026Review
- Engineering MSC Migration: Roles of Nanoparticles in Activating Migratory Pathways and Functions.International journal of molecular sciences · 2026Review
- Mesenchymal Stem Cell-Inspired Microneedle Platform for NIR-responsive Immunomodulation and Accelerated Chronic Wound Healing.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Harnessing extracellular vesicles for ischemic stroke management.Regenerative biomaterials · 2026Review
- Mesenchymal stem cell-derived exosomes: Regulators of progression and suppression in pancreatic cancer (Review).Oncology letters · 2026Review
- Targeting Strategies of Stem Cell-Derived Extracellular Vesicles in the Treatment of Cardiovascular Diseases.Stem cell reviews and reports · 2026Review
- Magnetic engineered bone mesenchymal stem cells-derived exosomes for targeted acute lung injury therapy.Stem cell research & therapy · 2025Article
- Analysis of the therapeutic effect and potential mechanism of FeMaterials today. Bio · 2025Article
- Cardiac Ischaemia-Reperfusion Injury: Pathophysiology, Therapeutic Targets and Future Interventions.Biomedicines · 2025Review
- Human induced pluripotent stem cell derived nanovesicles for cardiomyocyte protection and proliferation.Bioactive materials · 2025Article
- Engineering the future of nanomedicine: Strategic approaches to extracellular vesicle-based drug administration regimens.World journal of stem cells · 2025Review
- Therapeutic effect of mesenchymal stem cells and their derived exosomes in diseases.Molecular biomedicine · 2025Review
- The Potential of Mesenchymal Stem Cell-Derived Exosomes to Treat Diabetes Mellitus.Biomimetics (Basel, Switzerland) · 2025Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because of poor engraftment and safety concerns regarding mesenchymal stem cell (MSC) therapy, MSC-derived exosomes have emerged as an alternative cell-free therapy for myocardial infarction (MI). However, the diffusion of exosomes out of the infarcted heart following injection and the low productivity limit the potential of clinical applications. Here, we developed exosome-mimetic extracellular nanovesicles (NVs) derived from iron oxide nanoparticles (IONPs)-incorporated MSCs (IONP-MSCs). The retention of injected IONP-MSC-derived NVs (IONP-NVs) within the infarcted heart was markedly augmented by magnetic guidance. Furthermore, IONPs significantly increased the levels of therapeutic molecules in IONP-MSCs and IONP-NVs, which can reduce the concern of low exosome productivity. The injection of IONP-NVs into the infarcted heart and magnetic guidance induced an early shift from the inflammation phase to the reparative phase, reduced apoptosis and fibrosis, and enhanced angiogenesis and cardiac function recovery. This approach can enhance the therapeutic potency of an MSC-derived NV therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.